Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study
Advances in Therapy · 2025
DOI: 10.1007/s12325-024-03002-9 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Advances in Therapy, 2025. Verfasst von Swarna Khare und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, 8 Arlington Square West, Bracknell, RG12 1PU, UK. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Recombinant Fusion Proteins, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a complex metabolic disease with several treatment options. Some glucagon-like peptide 1 receptor agonists (GLP-1 RAs) approved by the European Medicines Agency include dulaglutide, subcutaneous (s.c.) semaglutide, and oral semaglutide. This study examines dulaglutide and semaglutide dosing patterns for T2DM in France and Italy. METHODS: IQVIA Longitudinal Prescription Data identified adults with T2DM prescribed dulaglutide or semaglutide between August 1, 2020 and December 31, 2022. Cohort 1 (incident) and cohort 2 (prevalent) users were followed for 12 months. RESULTS: In France and Italy, 255,571 and 350,853 patients, respectively, received at least one study GLP-1 RA. Most dulaglutide-naïve patients in France (62%) and approximately half in Italy (49%) started on 1.5 mg and remained on this dose for up to 12 months (France: 66% cohort 1, 88% cohort 2; Italy: 73% cohort 1, 87% cohort 2). In cohort 1, s.c. semaglutide users mostly started on 0.25 mg (France, 78%; Italy, 61%). At 12 months, s.c. semaglutide 1.0 mg was most prescribed (France: 58% cohort 1, 75% cohort 2; Italy: 59% cohort 2), with cohort 1 in Italy mostly receiving 0.5 mg (57%). Most oral semaglutide users in Italy started on 3.0 mg (78% cohort 1; 68% cohort 2), which was increased to 7.0 mg (62% cohort 1) and 14.0 mg (48% cohort 2) at 12 months. CONCLUSIONS: GLP-1 RA dosing patterns, although similar between France and Italy, were heterogeneous over time. As oral semaglutide and higher dulaglutide doses are recent to the market, additional real-world evidence is required to evaluate utilization patterns. Graphical abstract available for this article.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, 8 Arlington Square West, Bracknell, RG12 1PU, UK.
- Eli Lilly and Company, Indianapolis, IN, USA. osumili_beatrice@lilly.com.
- Eli Lilly and Company, Brussels, Belgium.
- IQVIA Inc., London, UK.
- IQVIA Inc., Milan, Italy.
- IQVIA Inc., Paris, France.
ORCID-Profile: Beatrice Osumili
Förderung
- Eli Lilly and Company
Zitieren
APA
Khare, S., Osumili, B., Debackere, N., Keapoletswe, K., Falato, S., Raoul, T., & Coles, B. (2025). Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study. Advances in Therapy. https://doi.org/10.1007/s12325-024-03002-9
Vancouver
Khare S, Osumili B, Debackere N, Keapoletswe K, Falato S, Raoul T, et al. Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study. Advances in Therapy. 2025. doi:10.1007/s12325-024-03002-9
BibTeX
@article{Khare2025,
author = {Khare, Swarna and Osumili, Beatrice and Debackere, Nele and Keapoletswe, Karabo and Falato, Serena and Raoul, Thomas and Coles, Briana},
title = {Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-024-03002-9}
}
EUVIMED